EGFR-TKI changes the tumor immune microenvironment, for example, by triggering programed death ligand-1 (PDL-1) expression and CD8 T-cell infiltration accompanied by tumor oncogenic mutations [3]. This evidence concerns the gene CD8A and neoplasm.